$PCYC Headlines Mid-caps rattle cage on all-ti
Post# of 74540
Posted On: 01/06/2015 12:45:40 PM
$PCYC Headlines
Mid-caps rattle cage on all-time highs 10:58 a.m. Nov. 13, 2014 - Michael Ashbaugh
Market technicals bend, but don’t break 9:21 a.m. Sept. 11, 2014 - Michael Ashbaugh
Charting the U.S. markets’ next technical tests 10:32 a.m. Aug. 4, 2014 - Michael Ashbaugh
5 stocks to watch 12:50 p.m. July 30, 2014 - The Trading Deck
Biotech hammered as ETFs down 5%, while some stocks fall 10% 12:55 p.m. April 10, 2014 - Russ Britt
Is biotech caught in a bubble, and is it popping? 12:13 p.m. April 8, 2014 - Russ Britt
S&P 500’s slow-motion breakout attempt ‘rages on’ 11:43 a.m. Feb. 27, 2014 - Michael Ashbaugh
FDA approval of leukemia treatment boosts shares of Pharmacyclics 1:57 p.m. Feb. 12, 2014 - Russ Britt
Pharmacyclics shares soar after panel says cancer drug met goals 12:09 p.m. Jan. 7, 2014 - Russ Britt
Gilead, Acura stand out on up day for stocks, Quest tumbles 10:27 a.m. Oct. 10, 2013 - Russ Britt
Health care leads S&P as St. Jude gets some good news from FDA 10:49 a.m. Oct. 4, 2013 - Russ Britt
Rough market day for Nektar, while Pharmacyclics and Regeneron soar 5:21 p.m. Sept. 26, 2013 - Russ Britt
Pharmacyclics shares jump after FDA accepts new cancer drug filing 11:09 a.m. Aug. 29, 2013 - Russ Britt
S&P 500 ventures to uncharted territory 11:21 a.m. July 18, 2013 - Michael Ashbaugh
Pharmacyclics seeks fast-track drug approval, makes double-digit gain 10:09 a.m. July 10, 2013 - Russ Britt
Onyx share surge lifts several boats in biotech harbor, including ETFs 10:33 a.m. July 1, 2013 - Russ Britt
Positives continue to build for the Nasdaq 12:31 p.m. June 4, 2013 - The Trading Deck
For the medium-term trader, setups galore 10:39 a.m. May 14, 2013 - The Trading Deck
After the close: Big gains for Pharmacyclics, Biogen, Warner 4:39 p.m. May 13, 2013 - Russ Britt
FDA gives 'breakthrough' designation to Merck drug 8:10 p.m. April 23, 2013 - MarketWatch.com
Imbruvica performs well in high-risk leukemia patients 12:15 p.m. Jan. 5, 2015 - Seeking Alpha
IMBRUVICA Data Demonstrates Efficacy in Previously Untreated and Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia Patients 8:02 a.m. Jan. 5, 2015 - benzinga.com
Individual Investor Portfolio: Solid Results, But Energy Sell-Off And Biotechnology Add Volatility 10:45 a.m. Jan. 2, 2015 - Seeking Alpha
Bull of the Day: Incyte (INCY) - Bull of the Day 1:00 a.m. Jan. 2, 2015 - Zacks.com
Idera Gets Orphan Drug Status for its Oncology Candidate - Analyst Blog 4:15 p.m. Dec. 31, 2014 - Zacks.com
DoctoRx Positions For 2015: I Have Cut Back On My Exposure To All Biotech Substantially 7:05 a.m. Dec. 30, 2014 - Seeking Alpha
13 Biotechnology Stocks to Buy Now 3:45 a.m. Dec. 24, 2014 - InvestorPlace.com
Pharmacyclics Reveals FDA Action Date for Imbruvica sNDA - Analyst Blog 6:05 p.m. Dec. 23, 2014 - Zacks.com
Pharmacyclics (PCYC) Is Water-Logged And Getting Wetter Today 12:10 p.m. Dec. 23, 2014 - TheStreet.com
Bull of the Day: Seattle Genetics (SGEN) - Bull of the Day 1:00 a.m. Dec. 19, 2014 - Zacks.com
11 Biotechnology Stocks to Buy Now 3:15 a.m. Dec. 17, 2014 - InvestorPlace.com
Nasdaq makes annual changes to Biotechnology Index 12:36 p.m. Dec. 15, 2014 - Seeking Alpha
11 Very Popular Stocks Now Valued Over 50 Times Earnings 7:11 a.m. Dec. 10, 2014 - 247WallSt.com
9 Biotechnology Stocks to Buy Now 4:30 a.m. Dec. 10, 2014 - InvestorPlace.com
Pharmacyclics Presents Imbruvica Data at the ASH Meeting - Analyst Blog 5:10 p.m. Dec. 9, 2014 - Zacks.com
Pharmacyclics Reports IMRUVICA Data Shows Safety, Durability of Response at Two-Year Follow-Up in Mantle Cell Lymphoma 8:02 a.m. Dec. 9, 2014 - benzinga.com
Pharmacyclics (PCYC) Launches U.S.-Based CLL Registry - Analyst Blog 6:50 p.m. Dec. 8, 2014 - Zacks.com
Can Pharmacyclics (PCYC) Run Higher on Strong Earnings Estimate Revisions? (Revised) - Tale of the Tape 8:35 a.m. Dec. 4, 2014 - Zacks.com
Can Pharmacyclics (PCYC) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape 8:41 a.m. Dec. 3, 2014 - Zacks.com
10 Biotechnology Stocks to Buy Now 4:15 a.m. Dec. 3, 2014 - InvestorPlace.com
Annual Changes to the NASDAQ Biotechnology Index 7:10 a.m. Dec. 15, 2014 - GlobeNewswire
Data From Phase 2 Clinical Trial of TG-1101 (Ublituximab) and Ibrutinib Shows Compelling Clinical Activity in Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia (CLL) 1:43 p.m. Dec. 8, 2014 - GlobeNewswire
Critical Alerts For Nuverra Environmental Solutions, Marvell Technology, Pharmacyclics, Aeropostale and Rockwell Medical Released By InvestorsObserver 9:31 a.m. Nov. 21, 2014 - PR Newswire - PRF
Collaboration, Breakthrough Therapy Designation, Clinical Trial Data, Voting Rights, and Financial Results - Research Reports on Johnson & Johnson, Merck, Amgen, Shire and HCA 8:50 a.m. Nov. 7, 2014 - PR Newswire - PRF
Keith Lui Joins Versartis to Lead Global Marketing Efforts 8:32 a.m. Nov. 6, 2014 - GlobeNewswire
Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 7:40 a.m. Oct. 30, 2014 - PR Newswire - PRF
Pharmacyclics Announces Conference Call to Discuss Third Quarter Financial Results 5:11 p.m. Oct. 28, 2014 - PR Newswire - PRF
New Medicare Plan, Clinical Study Results, ANDA Filing Confirmation, Strategic Collaboration, and Merger Termination - Research Reports on UnitedHealth, Celgene, Actavis, Bristol-Myers Squibb and Salix 8:10 a.m. Oct. 22, 2014 - PR Newswire - PRF
IMBRUVICA® (ibrutinib) Supplemental New Drug Application Submitted to the U.S. FDA for Waldenstrom's macroglobulinemia 7:05 a.m. Oct. 20, 2014 - PR Newswire - PRF
Pharmacyclics Files Supplemental New Drug Application for IMBRUVICA® for Waldenstrom's Macroglobulinemia 7:00 a.m. Oct. 20, 2014 - PR Newswire - PRF
IMBRUVICA® (ibrutinib) Now Approved in Europe for Treatment of Two Blood Cancers 7:49 a.m. Oct. 17, 2014 - PR Newswire - PRF
Biotech Stocks Technical Insight - Incyte, Regado Biosciences, ACADIA Pharma, Pharmacyclics, and Raptor Pharma 7:45 a.m. Sept. 26, 2014 - PR Newswire - PRF
Pharmacyclics and Servier Agree to Conclude Pan-HDAC Inhibitor Collaboration 3:01 p.m. Sept. 25, 2014 - PR Newswire - PRF
New Product Launch, Accelerated Drug Approvals, Study Initiation, and Market Activity - Research Reports on Johnson & Johnson, Merck, Medtronic, Pharmacyclics and NPS Pharma 8:15 a.m. Sept. 15, 2014 - PR Newswire - PRF
Financing Strategies, Financing Packages, Recognitions, Technical Updates, and Appointments - Research Reports on Aon, U.S. Bancorp, Ally Financial, Teva and Pharmacyclics 8:10 a.m. Aug. 22, 2014 - PR Newswire - PRF
Pharmacyclics Appoints Chief Commercial Officer 3:05 p.m. Aug. 18, 2014 - PR Newswire - PRF
Technical Summary on Biotech Equities -- Alkermes, Amarin, Array BioPharma, Navidea Biopharma, and Pharmacyclics Inc. 8:00 a.m. Aug. 18, 2014 - PR Newswire - PRF
Drug Approvals and Earnings Releases - Research Reports on Bristol-Myers, Johnson & Johnson, Merck, Pharmacyclics and Amgen 7:50 a.m. Aug. 4, 2014 - PR Newswire - PRF
Pharmacyclics Reports Second Quarter 2014 Results 3:04 p.m. July 31, 2014 - PR Newswire - PRF
Critical Alerts For Silicon Motion Technology, Pharmacyclics, 3D Systems, Walgreen, and Neurocrine Biosciences Released By InvestorsObserver 8:31 a.m. July 30, 2014 - PR Newswire - PRF
Mid-caps rattle cage on all-time highs 10:58 a.m. Nov. 13, 2014 - Michael Ashbaugh
Market technicals bend, but don’t break 9:21 a.m. Sept. 11, 2014 - Michael Ashbaugh
Charting the U.S. markets’ next technical tests 10:32 a.m. Aug. 4, 2014 - Michael Ashbaugh
5 stocks to watch 12:50 p.m. July 30, 2014 - The Trading Deck
Biotech hammered as ETFs down 5%, while some stocks fall 10% 12:55 p.m. April 10, 2014 - Russ Britt
Is biotech caught in a bubble, and is it popping? 12:13 p.m. April 8, 2014 - Russ Britt
S&P 500’s slow-motion breakout attempt ‘rages on’ 11:43 a.m. Feb. 27, 2014 - Michael Ashbaugh
FDA approval of leukemia treatment boosts shares of Pharmacyclics 1:57 p.m. Feb. 12, 2014 - Russ Britt
Pharmacyclics shares soar after panel says cancer drug met goals 12:09 p.m. Jan. 7, 2014 - Russ Britt
Gilead, Acura stand out on up day for stocks, Quest tumbles 10:27 a.m. Oct. 10, 2013 - Russ Britt
Health care leads S&P as St. Jude gets some good news from FDA 10:49 a.m. Oct. 4, 2013 - Russ Britt
Rough market day for Nektar, while Pharmacyclics and Regeneron soar 5:21 p.m. Sept. 26, 2013 - Russ Britt
Pharmacyclics shares jump after FDA accepts new cancer drug filing 11:09 a.m. Aug. 29, 2013 - Russ Britt
S&P 500 ventures to uncharted territory 11:21 a.m. July 18, 2013 - Michael Ashbaugh
Pharmacyclics seeks fast-track drug approval, makes double-digit gain 10:09 a.m. July 10, 2013 - Russ Britt
Onyx share surge lifts several boats in biotech harbor, including ETFs 10:33 a.m. July 1, 2013 - Russ Britt
Positives continue to build for the Nasdaq 12:31 p.m. June 4, 2013 - The Trading Deck
For the medium-term trader, setups galore 10:39 a.m. May 14, 2013 - The Trading Deck
After the close: Big gains for Pharmacyclics, Biogen, Warner 4:39 p.m. May 13, 2013 - Russ Britt
FDA gives 'breakthrough' designation to Merck drug 8:10 p.m. April 23, 2013 - MarketWatch.com
Imbruvica performs well in high-risk leukemia patients 12:15 p.m. Jan. 5, 2015 - Seeking Alpha
IMBRUVICA Data Demonstrates Efficacy in Previously Untreated and Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia Patients 8:02 a.m. Jan. 5, 2015 - benzinga.com
Individual Investor Portfolio: Solid Results, But Energy Sell-Off And Biotechnology Add Volatility 10:45 a.m. Jan. 2, 2015 - Seeking Alpha
Bull of the Day: Incyte (INCY) - Bull of the Day 1:00 a.m. Jan. 2, 2015 - Zacks.com
Idera Gets Orphan Drug Status for its Oncology Candidate - Analyst Blog 4:15 p.m. Dec. 31, 2014 - Zacks.com
DoctoRx Positions For 2015: I Have Cut Back On My Exposure To All Biotech Substantially 7:05 a.m. Dec. 30, 2014 - Seeking Alpha
13 Biotechnology Stocks to Buy Now 3:45 a.m. Dec. 24, 2014 - InvestorPlace.com
Pharmacyclics Reveals FDA Action Date for Imbruvica sNDA - Analyst Blog 6:05 p.m. Dec. 23, 2014 - Zacks.com
Pharmacyclics (PCYC) Is Water-Logged And Getting Wetter Today 12:10 p.m. Dec. 23, 2014 - TheStreet.com
Bull of the Day: Seattle Genetics (SGEN) - Bull of the Day 1:00 a.m. Dec. 19, 2014 - Zacks.com
11 Biotechnology Stocks to Buy Now 3:15 a.m. Dec. 17, 2014 - InvestorPlace.com
Nasdaq makes annual changes to Biotechnology Index 12:36 p.m. Dec. 15, 2014 - Seeking Alpha
11 Very Popular Stocks Now Valued Over 50 Times Earnings 7:11 a.m. Dec. 10, 2014 - 247WallSt.com
9 Biotechnology Stocks to Buy Now 4:30 a.m. Dec. 10, 2014 - InvestorPlace.com
Pharmacyclics Presents Imbruvica Data at the ASH Meeting - Analyst Blog 5:10 p.m. Dec. 9, 2014 - Zacks.com
Pharmacyclics Reports IMRUVICA Data Shows Safety, Durability of Response at Two-Year Follow-Up in Mantle Cell Lymphoma 8:02 a.m. Dec. 9, 2014 - benzinga.com
Pharmacyclics (PCYC) Launches U.S.-Based CLL Registry - Analyst Blog 6:50 p.m. Dec. 8, 2014 - Zacks.com
Can Pharmacyclics (PCYC) Run Higher on Strong Earnings Estimate Revisions? (Revised) - Tale of the Tape 8:35 a.m. Dec. 4, 2014 - Zacks.com
Can Pharmacyclics (PCYC) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape 8:41 a.m. Dec. 3, 2014 - Zacks.com
10 Biotechnology Stocks to Buy Now 4:15 a.m. Dec. 3, 2014 - InvestorPlace.com
Annual Changes to the NASDAQ Biotechnology Index 7:10 a.m. Dec. 15, 2014 - GlobeNewswire
Data From Phase 2 Clinical Trial of TG-1101 (Ublituximab) and Ibrutinib Shows Compelling Clinical Activity in Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia (CLL) 1:43 p.m. Dec. 8, 2014 - GlobeNewswire
Critical Alerts For Nuverra Environmental Solutions, Marvell Technology, Pharmacyclics, Aeropostale and Rockwell Medical Released By InvestorsObserver 9:31 a.m. Nov. 21, 2014 - PR Newswire - PRF
Collaboration, Breakthrough Therapy Designation, Clinical Trial Data, Voting Rights, and Financial Results - Research Reports on Johnson & Johnson, Merck, Amgen, Shire and HCA 8:50 a.m. Nov. 7, 2014 - PR Newswire - PRF
Keith Lui Joins Versartis to Lead Global Marketing Efforts 8:32 a.m. Nov. 6, 2014 - GlobeNewswire
Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 7:40 a.m. Oct. 30, 2014 - PR Newswire - PRF
Pharmacyclics Announces Conference Call to Discuss Third Quarter Financial Results 5:11 p.m. Oct. 28, 2014 - PR Newswire - PRF
New Medicare Plan, Clinical Study Results, ANDA Filing Confirmation, Strategic Collaboration, and Merger Termination - Research Reports on UnitedHealth, Celgene, Actavis, Bristol-Myers Squibb and Salix 8:10 a.m. Oct. 22, 2014 - PR Newswire - PRF
IMBRUVICA® (ibrutinib) Supplemental New Drug Application Submitted to the U.S. FDA for Waldenstrom's macroglobulinemia 7:05 a.m. Oct. 20, 2014 - PR Newswire - PRF
Pharmacyclics Files Supplemental New Drug Application for IMBRUVICA® for Waldenstrom's Macroglobulinemia 7:00 a.m. Oct. 20, 2014 - PR Newswire - PRF
IMBRUVICA® (ibrutinib) Now Approved in Europe for Treatment of Two Blood Cancers 7:49 a.m. Oct. 17, 2014 - PR Newswire - PRF
Biotech Stocks Technical Insight - Incyte, Regado Biosciences, ACADIA Pharma, Pharmacyclics, and Raptor Pharma 7:45 a.m. Sept. 26, 2014 - PR Newswire - PRF
Pharmacyclics and Servier Agree to Conclude Pan-HDAC Inhibitor Collaboration 3:01 p.m. Sept. 25, 2014 - PR Newswire - PRF
New Product Launch, Accelerated Drug Approvals, Study Initiation, and Market Activity - Research Reports on Johnson & Johnson, Merck, Medtronic, Pharmacyclics and NPS Pharma 8:15 a.m. Sept. 15, 2014 - PR Newswire - PRF
Financing Strategies, Financing Packages, Recognitions, Technical Updates, and Appointments - Research Reports on Aon, U.S. Bancorp, Ally Financial, Teva and Pharmacyclics 8:10 a.m. Aug. 22, 2014 - PR Newswire - PRF
Pharmacyclics Appoints Chief Commercial Officer 3:05 p.m. Aug. 18, 2014 - PR Newswire - PRF
Technical Summary on Biotech Equities -- Alkermes, Amarin, Array BioPharma, Navidea Biopharma, and Pharmacyclics Inc. 8:00 a.m. Aug. 18, 2014 - PR Newswire - PRF
Drug Approvals and Earnings Releases - Research Reports on Bristol-Myers, Johnson & Johnson, Merck, Pharmacyclics and Amgen 7:50 a.m. Aug. 4, 2014 - PR Newswire - PRF
Pharmacyclics Reports Second Quarter 2014 Results 3:04 p.m. July 31, 2014 - PR Newswire - PRF
Critical Alerts For Silicon Motion Technology, Pharmacyclics, 3D Systems, Walgreen, and Neurocrine Biosciences Released By InvestorsObserver 8:31 a.m. July 30, 2014 - PR Newswire - PRF
(0)
(0)Scroll down for more posts ▼